Indication: Before instituting treatment with Ceftriaxone for Injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP and other antibacterial drugs, Ceftriaxone for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA Streptococcus pneumoniae, Haemophilus influenzae Moraxella catarrhalis NOTE: In one study lower clinical cure rates were observed with a single dose of Ceftriaxone for Injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose Ceftriaxone for Injection, USP and the comparator. The potentially lower clinical cure rate of Ceftriaxone for Injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis Peptostreptococcus URINARY TRACT INFECTIONS (complicated and uncomplicated) Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) Neisseria gonorrhoeae, Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE Neisseria gonorrhoeae. Chlamydia trachomatis Chlamydia trachomatis BACTERIAL SEPTICEMIA Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae Klebsiella pneumoniae. BONE AND JOINT INFECTIONS Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae Enterobacter INTRA-ABDOMINAL INFECTIONS Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium Clostridium difficile Peptostreptococcus MENINGITIS Haemophilus influenzae, Neisseria meningitidis Streptococcus pneumoniae. Staphylococcus epidermidis Escherichia coli. *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: , , When administered prior to surgical procedures for which it is indicated, a single 1 g dose of Ceftriaxone for Injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Indication: Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1. 1 Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1. 2 Skin and skin structure infections in adults ( 1. 3 Female pelvic infections in adults ( 1. 4 Community-acquired pneumonia in adults ( 1. 5 To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 6 Piperacillin and tazobactam for injection, USP is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli Bacteroides fragilis B. thetaiotaomicron B. vulgatus Piperacillin and tazobactam for injection, USP is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus Acinetobacter baumannii Haemophilus influenzae Klebsiella pneumoniae Pseudomonas aeruginosa P. aeruginosa [see Dosage and Administration ( 2 Piperacillin and tazobactam for injection, USP is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus Piperacillin and tazobactam for injection, USP is indicated in adults for the treatment of postpartum endometritis or pelvic inflammatory disease caused by beta-lactamase producing isolates of Escherichia coli Piperacillin and tazobactam for injection, USP is indicated in adults for the treatment of community-acquired pneumonia (moderate severity only) caused by beta-lactamase producing isolates of Haemophilus influenzae To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection, USP and other antibacterial drugs, piperacillin and tazobactam for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Indication: Piperacillin and Tazobactam for Injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1. 1 Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1. 2 Skin and skin structure infections in adults ( 1. 3 Female pelvic infections in adults ( 1. 4 Community-acquired pneumonia in adults ( 1. 5 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and Tazobactam for Injection and other antibacterial drugs, Piperacillin and Tazobactam for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 6 Piperacillin and tazobactam for injection, USP is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli Bacteroides fragilis B. fragilis, B. thetaiotaomicron, B. Piperacillin and tazobactam for injection, USP is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus Acinetobacter baumannii Haemophilus influenzae Klebsiella pneumoniae Pseudomonas aeruginosa P. aeruginosa [see Dosage and Administration ( 2 Piperacillin and tazobactam for injection, USP is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus. Piperacillin and tazobactam for injection, USP is indicated in adults for the treatment of postpartum endometritis or pelvic inflammatory disease caused by beta-lactamase producing isolates of Escherichia coli. Piperacillin and tazobactam for injection, USP is indicated in adults for the treatment of community-acquired pneumonia (moderate severity only) caused by beta-lactamase producing isolates of Haemophilus influenzae. To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection, USP and other antibacterial drugs, piperacillin and tazobactam for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Indication: Piperacillin and Tazobactam for Injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1. 1 Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1. 2 Skin and skin structure infections in adults ( 1. 3 Female pelvic infections in adults ( 1. 4 Community-acquired pneumonia in adults ( 1. 5 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and Tazobactam for Injection and other antibacterial drugs, Piperacillin and Tazobactam for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 6 Piperacillin and tazobactam for injection, USP is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli Bacteroides fragilis B. thetaiotaomicron B. vulgatus Piperacillin and tazobactam for injection, USP is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus Acinetobacter baumannii Haemophilus influenzae Klebsiella pneumoniae Pseudomonas aeruginosa P. aeruginosa [see Dosage and Administration ( 2 Piperacillin and tazobactam for injection, USP is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus Piperacillin and tazobactam for injection, USP is indicated in adults for the treatment of postpartum endometritis or pelvic inflammatory disease caused by beta-lactamase producing isolates of Escherichia coli Piperacillin and tazobactam for injection, USP is indicated in adults for the treatment of community-acquired pneumonia (moderate severity only) caused by beta-lactamase producing isolates of Haemophilus influenzae To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection, USP and other antibacterial drugs, piperacillin and tazobactam for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Indication: INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFOBID and other antibacterial drugs. CEFOBID should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CEFOBID is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory Tract Infections S. pneumoniae, H. influenzae, S. pyogenes Efficacy against this organism in this organ system was studied in fewer than 10 infections. aeruginosa, Klebsiella pneumoniae, E. coli, Proteus mirabilis, Enterobacter Peritonitis and Other Intra-abdominal Infections E. aeruginosa Bacteroides fragilis Bacterial Septicemia S. pneumoniae, S. agalactiae S. aureus, Pseudomonas aeruginosa E. coli, Klebsiella Klebsiella pneumoniae, Proteus Clostridioides Infections of the Skin and Skin Structures S. Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract N. gonorrhoeae, S. epidermidis S. agalactiae, E. coli, Clostridioides Bacteroides Bacteroides fragilis Cefobid registered Chlamydia trachomatis C. trachomatis Urinary Tract Infections Escherichia coli Pseudomonas aeruginosa Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, in vitro in vivo Synergy between CEFOBID and aminoglycosides has been demonstrated with many gram-negative bacilli. However, such enhanced activity of these combinations is not predictable. If such therapy is considered, in vitro PRECAUTIONS DOSAGE AND ADMINISTRATION.
Enterococcal Infections
Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, in vitro in vivo

Indication: INDICATIONS AND USAGE
Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: Caused by Streptococcus pneumoniae Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis Serratia marcescens Caused by Streptococcus pneumoniae, Haemophilus influenzae Moraxella catarrhalis NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES Caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes streptococci Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis Peptostreptococcus Caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii Klebsiella pneumoniae Caused by Neisseria gonorrhoeae Neisseria gonorrhoeae Caused by Neisseria gonorrhoeae Chlamydia trachomatis Chlamydia trachomatis Caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae Klebsiella pneumoniae Caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae Enterobacter Caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium Clostridium difficile Peptostreptococcus Caused by Haemophilus influenzae, Neisseria meningitidis Streptococcus pneumoniae Staphylococcus epidermidis Escherichia coli* * Efficacy for this organism in this organ system was studied in fewer than ten infections. The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e. , vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e. , during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone provides protection from most infections due to susceptible organisms throughout the course of the procedure.
Lower Respiratory Tract Infections
Caused by Streptococcus pneumoniae Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis Serratia marcescens
Acute Bacterial Otitis Media
Caused by Streptococcus pneumoniae, Haemophilus influenzae Moraxella catarrhalis NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES
Skin and Skin Structure Infections
Caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes streptococci Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis Peptostreptococcus
Urinary Tract Infections (complicated and uncomplicated)
Caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii Klebsiella pneumoniae
Uncomplicated Gonorrhea (cervical/urethral and rectal)
Caused by Neisseria gonorrhoeae Neisseria gonorrhoeae
Pelvic Inflammatory Disease
Caused by Neisseria gonorrhoeae Chlamydia trachomatis Chlamydia trachomatis
Bacterial Septicemia
Caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae Klebsiella pneumoniae
Bone and Joint Infections
Caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae Enterobacter
Intra-abdominal Infections
Caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium Clostridium difficile Peptostreptococcus
Meningitis
Caused by Haemophilus influenzae, Neisseria meningitidis Streptococcus pneumoniae Staphylococcus epidermidis Escherichia coli* * Efficacy for this organism in this organ system was studied in fewer than ten infections.
Surgical Prophylaxis
The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone provides protection from most infections due to susceptible organisms throughout the course of the procedure.
Infections and Infestations
Genital fungal infection (0.1%)
Genitourinary
Moniliasis or vaginitis were reported occasionally (<1%).

Indication: Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: 1. 5 To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 6 Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli Bacteroides fragilis B. thetaiotaomicron B. vulgatus Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa P. aeruginosa [see Dosage and Administration ( 2 Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus Piperacillin and tazobactam for injection is indicated in adults for the treatment of postpartum endometritis or pelvic inflammatory disease caused by beta-lactamase producing isolates of Escherichia coli Piperacillin and tazobactam for injection is indicated in adults for the treatment of community-acquired pneumonia (moderate severity only) caused by beta-lactamase producing isolates of Haemophilus influenzae To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Indication: Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: 1. 5 To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 6 Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis B. thetaiotaomicron B. vulgatus Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa see Dosage and Administration ( 2 Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus Piperacillin and tazobactam for injection is indicated in adults for the treatment of postpartum endometritis or pelvic inflammatory disease caused by beta-lactamase producing isolates of Escherichia coli Piperacillin and tazobactam for injection is indicated in adults for the treatment of community-acquired pneumonia (moderate severity only) caused by beta-lactamase producing isolates of Haemophilus influenzae. To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Indication: To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFOBID and other antibacterial drugs. CEFOBID should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CEFOBID is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory Tract Infections S. pneumoniae H. influenzae S. pyogenes Efficacy against this organism in this organ system was studied in fewer than 10 infections. aeruginosa Klebsiella pneumoniae E. coli Proteus mirabilis Enterobacter Peritonitis and Other Intra-abdominal Infections E. aeruginosa, Bacteroides fragilis Bacterial Septicemia S. pneumoniae S. agalactiae S. aureus Pseudomonas aeruginosa E. coli Klebsiella Klebsiella pneumoniae Proteus Clostridioides Infections of the Skin and Skin Structures S. aeruginosa Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract N. gonorrhoeae S. epidermidis S. agalactiae E. coli Clostridioides Bacteroides Bacteroides fragilis Cefobid registered Chlamydia trachomatis C. trachomatis Urinary Tract Infections Escherichia coli Pseudomonas aeruginosa Enterococcal Infections: peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections in vitro in vivo Synergy between CEFOBID and aminoglycosides has been demonstrated with many gram-negative bacilli. However, such enhanced activity of these combinations is not predictable. If such therapy is considered, in vitro PRECAUTIONS DOSAGE AND ADMINISTRATION.

Indication: INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFOBID and other antibacterial drugs. CEFOBID should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CEFOBID is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory Tract Infections S. pneumoniae, H. influenzae, S. pyogenes Efficacy against this organism in this organ system was studied in fewer than 10 infections. aeruginosa, Klebsiella pneumoniae, E. coli, Proteus mirabilis, Enterobacter Peritonitis and Other Intra-abdominal Infections E. aeruginosa Bacteroides fragilis Bacterial Septicemia S. pneumoniae, S. agalactiae S. aureus, Pseudomonas aeruginosa E. coli, Klebsiella Klebsiella pneumoniae, Proteus Clostridioides Infections of the Skin and Skin Structures S. Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract N. gonorrhoeae, S. epidermidis S. agalactiae, E. coli, Clostridioides Bacteroides Bacteroides fragilis Cefobid registered Chlamydia trachomatis C. trachomatis Urinary Tract Infections Escherichia coli Pseudomonas aeruginosa Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, in vitro in vivo Synergy between CEFOBID and aminoglycosides has been demonstrated with many gram-negative bacilli. However, such enhanced activity of these combinations is not predictable. If such therapy is considered, in vitro PRECAUTIONS DOSAGE AND ADMINISTRATION.
Enterococcal Infections
Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, in vitro in vivo